Several GLUT1 inhibitors, including WZB117, STF-31, NV-5440, and BAY-876 are described, but while GLUT1 is the primary transporter affected by cancer signaling, additional glucose transporters promote tumor cell survival and often gain function upon GLUT1 inhibition – all of which provides a rationale for targeting multiple GLUTs [22–25]. This evidence concerns the gene SLC2A1 and neoplasm.